Advancing psoriasis management with a novel, targeted T-cell modulator

Drugs of Today

Volumn 40, Issue 11, 2004, Pages 889-899

  Papp, Kim A ^a  

^a PROBITY MEDICAL RESEARCH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EFALIZUMAB; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOMODULATING AGENT; PLACEBO; MONOCLONAL ANTIBODY;

ACNE; AUTOIMMUNE DISEASE; BACKACHE; CHILL; CLINICAL RESEARCH; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EFFECTOR CELL; FEVER; FLU LIKE SYNDROME; HEADACHE; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; INFECTION; KERATINOCYTE; LONG TERM CARE; MAJOR CLINICAL STUDY; MEDICAL RESEARCH; MYALGIA; NAUSEA; OPEN STUDY; PAIN; PHASE 3 CLINICAL TRIAL; PSORIASIS; QUALITY OF LIFE; REVIEW; SIDE EFFECT; T LYMPHOCYTE ACTIVATION; ANIMAL; DRUG EFFECT; HOSPITALIZATION; IMMUNOLOGY; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS, PHASE III; HUMANS; PSORIASIS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES;

EID: 11844281451     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2004.40.11.872578     Document Type: Review

References (44)

1. Rapp, S.R., Feldman, S.R., Exum, M.L., Fleischer, A.B.J., Reboussin, D.M. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999, 41: 401-7.
2. Mueller, W., Herrmann, B. Cyclosporin A for psoriasis. N Engl J Med 1979, 301: 555.
3. Mrowietz, U., Ruzicka, T. Cyclosporin A for psoriasis. Dermatologic Ther 1999, 11: 60-6.
4. Gottlieb, S.L., Gilleaudeau, P., Johnson, R. et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1995, 1: 442-7.
5. Martin, A., Gutiérrez, E., Muglia, J. et al. A multicenter dose-escalation trial with denileukin diftitox (ONTAK, DAB(389)IL-2) in patients with severe psoriasis. J Am Acad Dermatol 2001, 45: 871-81.
6. Wrone-Smith, T., Nickoloff, BJ. Dermal injection of immunocytes induces psoriasis. J Clin Invest 1996 Oct 15, 98: 1878-87.
7. Nickoloff, B.J. The immunologic and genetic basis of psoriasis. Arch Dermatol 1999, 135: 1104-10.
8. Lebwohl, M. Psoriasis. Lancet 2003 Apr 5, 361: 1197-1204.
9. Prinz, J. The role of T cells in psoriasis. J Eur Acad Dermatol Venereol 2003, 17: 257-70.
10. Hwang, ST. Mechanisms of T-cell homing to skin. Adv Dermatol 2001, 17: 211-41.
11. Mehlis, S.L., Gordon, K.B. The immunology of psoriasis and biologic immunotherapy. J Am Acad Dermatol 2003, 49: S44-S50.
12. Krueger, J.G. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002, 46: 1-23.
13. Werther, W.A., Gonzalez, T.N., O'Connor, S.J. et al. Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J Immunol 1996 Dec 12, 157: 4986-95.
14. Gottlieb, A.B., Miller, B., Lowe, N. et al. Sub-cutaneously administered efalizumab (anti-CD11a) improves signs and symptoms of moderate to severe plaque psoriasis. J Cutan Med Surg 2003, 7: 198-207.
15. Bauer, R.J., Dedrick, R.L., White, M.L., Murray, MJ., Garovoy, M.R. Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis. J Pharmacokinet Biopharm 1999, 27: 397-420.
16. Gottlieb, A., Krueger, J.G., Bright, R. et al. Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J Am Acad Dermatol 2000, 42: 428-35.
17. Gottlieb, A.B., Krueger, J.G., Wittkowski, K., Dedrick, R., Walicke, P.A., Garovoy, M. Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch Dermatol 2002, 138: 591-600.
18. Papp, K., Bissonnette, R., Krueger, J.G. et al. The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. J Am Acad Dermatol 2001, 45: 665-74.
19. Gordon, K.B., Papp, K.A., Hamilton, T.K. et al. Efalizumab for patients with moderate to severe plaque psoriasis: A randomized controlled trial. JAMA 2003 Dec 17, 290: 3073-80.
20. Lebwohl, M., Tyring, S.K., Hamilton, T.K. et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003, 349: 2004-13.
21. Menter, M.A., Krueger, G.G., Feldman, S.R., Weinstein, G.D. Psoriasis treatment 2003 at the new millennium: Position paper on behalf of the authors. J Am Acad Dermatol 2003, 49: S39-S43.
22. Langley, R.G.B. The efficacy and safety of efalizumab for patients with moderate to severe plaque psoriasis. 12th Annual Congress of the European Academy of Dermatology and Venereology (October 15-18, Barcelona) 2003; Poster 27.40.
23. Gordon, K.B., Leonardi, C., Harvey, D. et al. Continuous treatment improves outcomes in patients with moderate to severe plaque psoriasis treated with subcutaneous (SC) efalizumab (anti-CD11a): Results from the phase III trial ACD2058g. 60th Annual Meeting of the American Academy of Dermatology (February 22-27, New Orleans) 2002, Poster 585.
24. Gottlieb, A.B., Gordon, K.B., Caro, I. et al. Long-term efalizumab therapy maintains Psoriasis Area and Severity Index improvement: Preliminary Results from an open-label trial. 62nd American Academy of Dermatology (February 6-11, Washington, DC) 2004. Poster 611.
25. Finlay, A.Y., Khan, G.K. Dermatology Life Quality Index (DLQI)- a simple practical measure for routine clinical use. Clin Exp Dermatol 1994, 19: 210-6.
26. Finlay, A.Y. Skin disease disability: Measuring its magnitude. Keio J Med 1998, 47: 131-4.
27. Chren, M.M., Lasek, R.J., Flocke, S.A., Zyzanski, S.J. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol 1997, 133: 1433-40.
28. Gupta, M.A., Gupta, A.K., Kirkby, S. et al. Pruritus in psoriasis. A prospective study of some psychiatric and dermatologic correlates. Arch Dermatol 1988, 124: 1052-7.
29. Szepietowski, J.C., Reich, A., Wisnicka, B. Itching in patients suffering from psoriasis. Acta Dermatovenerol Croat 2002, 10: 221-6.
30. Yosipovitch, G., Goon, A., Wee, J., Chan, Y.H., Goh, C.L. The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis. Br J Dermatol 2000, 143: 969-73.
31. Shikiar, R., Bresnahan, B.W., Stone, S.P., Thompson, C., Koo, J., Revicki, D.A. Validity and reliability of patient reported outcomes used in psoriasis: Results from two randomized clinical trials. Health Quality Life Outcomes 2003, 1-9.
32. Feldman, S.R., Carey, W., Goldman, M. et al. Subcutaneous (SC) efalizumab (anti-CD11) significantly improves patient reported symptoms in patients with moderate to severe plaque psoriasis. Summer Meeting of the American Academy of Dermatology (July 31-August 4, New York) 2002. Poster 53.
33. Feldman, S.R., Miller, B., Powers, J. et al. Subcutaneous (SC) efalizumab (anti-CD11a) improves quality of life in patients with moderate to severe plaque psoriasis. 60th Annual Meeting of the American Academy of Dermatology (February 22-27, New Orleans) 2002, Poster 587.
34. Gordon, K.B., Siegfried, E.G., Carey, W. et al. Impact of 24 weeks of continuous efalizumab therapy on patient-reported outcomes in patients with moderate to severe plaque psorasis. American Academy of Dermatology Summer Meeting (July 25-29, Chicago) 2003, Poster 42.
35. Rosoph, L. Safety of efalizumab, a humanized monoclonal antibody, in patients with moderate to severe plaque psoriasis. 12th Annual Congress of the European Academy of Dermatology and Venereology (October 15-18, Barcelona) 2003.
36. Raptiva™ (efalizumab) package insert. Genentech, Inc., South San Francisco, Calif., October 2003.
37. Lebwohl, M.G., Walicke, P.A., Wang, X., Compton, P.G., Kaplowitz, H. A review of the risk of infection with efalizumab therapy. 9th International Psoriasis Symposium (June 18-22, New York) 2003, Poster 26.
38. Leonardi, C.L., Walicke, P.A., Wang, X., Compton, P.G., Kaplowitz, H., Menter, A. A review of the risk of systemic malignancy with efalizumab therapy. 9th International Psoriasis Symposium (June 18-22, New York) 2003, Poster 28.
39. Menter, A., Toth, D., Glazer, S. et al. Efficacy and safety of 24-week continuous efalizumab therapy in patients with moderate to severe plaque psoriasis. Meeting of the American Association of Dermatology Academy (July 25-29, Chicago) 2003, Poster 44.
40. Gottlieb, A., Gordon, K., Caro, I., Li, N., Chastain, R., Leonardi, C. Long-term efalizumab therapy safely maintains Psoriasis Area and Severity Index improvement: Preliminary results from an open-label trial. 62nd Annual Meeting of the American Academy of Dermatology (February 6-11, Washington, DC) 2004, Poster 611.
41. Krueger, G., Koo, J., Lebwohl, M., Menter, A., Stern, R.S., Rolstad, T. The impact of psoriasis on quality of life: Results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001, 137: 280-4.
42. Salonen, S.H. The EUROPSO psoriasis patient study: Treatment history and satisfaction reported by 17,990 members of European psoriasis patient associations. Spring Symposium of the European Academy of Dermatology and Venereology (February 27-March 1, Malta) 2003.
43. Finlay, A.Y. Psoriasis from the patient's point of view. Arch Dermatol 2001, 137: 352-3.
44. Singri, P., West, D.P., Gordon, K.B. Biologic therapy for psoriasis: The new therapeutic frontier. Arch Dermatol 2002, 138: 657-63.